Discussion
In a large, ongoing clinical trial, a high dose of the oral therapy candidate brepocitinib was found to markedly reduce disease activity in most people with cutaneous sarcoidosis — a type of the rare autoimmune disease that affects the skin and currently has no approved treatment options. In fact,…